DICE Therapeutics, Inc. believes it could have a best-in-class oral drug in development for psoriasis based on positive data from a Phase I clinical trial testing DC-806, an oral small molecule antagonist of interleukin-17. The data are early, but the company's stock price shot up 79% to open 11 October at $44.18 on the news given how lucrative the commercial opportunity for effective oral options could be in a category dominated by injectable drugs.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?